A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113)
Withdrawn
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
The purpose of this trial is to study L-735,524, which is an inhibitor of the HIV protease
enzyme. It will be used with interleukin-2 in patients infected with HIV.
A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
1969-12-31
To determine the clinical efficacy of indinavir sulfate or placebo in combination with
zidovudine ( AZT ) and lamivudine ( 3TC ) in AIDS patients.
Protease inhibitors such as indinavir sulfate may be effective in patients with advanced HIV
disease who have received prior AZT therapy. Since studies suggest that triple drug therapy
may have an advantage over both monotherapy and two drug therapy, the combination of
indinavir sulfate with AZT and 3TC should be evaluated.
The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
1969-12-31
To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule
formulation of saquinavir or to indinavir following prolonged use of the original hard
capsule formulation of saquinavir results in an acute decrease in plasma HIV RNA.
Resistance to anti-HIV agents occurs with increasing duration of use. In vitro studies have
shown that cross-resistance occurs among protease inhibitors, although no clinical trials
have been conducted to examine antiretroviral activity with sequential use of protease
inhibitors or to determine whether saquinavir resistance can be overcome with higher
concentrations of the drug.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
